The realm of oncology has been revolutionized by the advent of targeted therapy, a novel approach that precisely targets cancer cells while sparing normal cells. This article provides a comprehensive overview of the potential of targeted therapy in modern oncology.
Targeted therapy, unlike traditional chemotherapy, aims to specifically interfere with cancer cell division and proliferation, thereby reducing damage to normal cells. It is based on our understanding of the genetic and molecular alterations that fuel cancer growth. This therapy employs small molecules or monoclonal antibodies to inhibit these specific targets.
Targeted therapies can be broadly classified into two categories: small molecule drugs and monoclonal antibodies. Small molecule drugs are small enough to enter cells easily, hence they are often used against intracellular targets. Monoclonal antibodies, on the other hand, are too large to enter cells, so they are used to target extracellular factors and receptors.
Targeted therapy has transformed the treatment paradigm for several cancers, including breast, lung, and colorectal cancers. These therapies have shown significant efficacy in patients with specific genetic alterations, leading to improved survival rates and quality of life. Moreover, targeted therapies often have fewer side effects than traditional chemotherapy, making them a preferable treatment choice for many patients.
With the advent of next-generation sequencing and precision medicine, the future of targeted therapy looks promising. The development of new targeted agents and the identification of novel therapeutic targets will likely lead to more effective and personalized treatment strategies in oncology.
Targeted therapy has undeniably reshaped the landscape of cancer treatment. As we deepen our understanding of the molecular basis of cancer, the potential of targeted therapy will continue to grow, offering hope for improved patient outcomes in the future.
1.
Does Maintenance Therapy Extend Life in mCRC?
2.
What does it mean for Biden's prostate cancer to be 'aggressive'? A urologic surgeon explains
3.
Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement
4.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
5.
Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients
1.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
2.
Hypogammaglobulinemia: A Comprehensive Guide for Patients and Caregivers
3.
Personalized Survivorship Navigation in Precision Cancer Care
4.
Hematopoietic Stem Cell Exhaustion in Blood Disorders
5.
Hematopoietic Clonal Competition in Blood Disorders
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Advances in Modern Cancer Treatment
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
4.
Early Warning Signs of Cancer
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation